Fennec Pharmaceuticals (STU:RV41) FFO


STU:RV41 Fennec Pharmaceuticals Inc STU:RV41
59 GF Score
Price €9.25
GF Value €9.09
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Fennec Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

STU:RV41
59GF Score
Fennec Pharmaceuticals Inc STU:RV41
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fennec Pharmaceuticals (STU:RV41) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued. The current stock price of €9.25 is trading 1.8% above its estimated GF Value™ of €9.09. GuruFocus considers Fennec Pharmaceuticals to be Fairly Valued.

Key valuation signals for STU:RV41:

  • FFO:
  • GF Value™: €9.09 vs. price of €9.25 (1.8% above fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the STU:RV41 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fennec Pharmaceuticals Business Description

Other Exchanges FENC:USAFRX:Canada
Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
59GF Score

Get the complete analysis for STU:RV41

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.25
Price
€9.09
GF Value